China Regenerative Medicine International Limited stock analysis
Want to see HK:8158 full AI Analyst Report?
China Regenerative Medicine International Limited (8158) Stock Price & Analysis
8158 Stock Chart & Stats
- Day’s Range
- HKD 0.24 - HKD 0.24
- 52-Week Range
- HKD 0.06 - HKD 0.66
- Previous Close
- HKD 0.24
- Volume
- N/A
- Average Volume (3M)
- 13.40K
- Market Cap
- HKD 71.80M
- Enterprise Value
- HKD 130.75M
- Total Cash (Recent Filing)
- HKD 1.82M
- Total Debt (Recent Filing)
- HKD 38.25M
- Price to Earnings (P/E)
- 2.4
- Beta
- -0.47
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability
Strong TTM revenue growth combined with healthy gross and net margins indicates meaningful commercial traction and current earnings capacity. If maintained, this combination can strengthen internal funding, support continued investment in healthcare activities, and improve resilience over the next several quarters.
Deleveraging
The substantial reduction in leverage materially improves financial flexibility compared with the stressed 2023–2024 period. A stronger equity base and lower debt burden can reduce balance-sheet pressure, improve funding resilience, and give management more room to allocate capital toward operations.
Improved Cash Generation
The sharp improvement in operating and free cash flow is a constructive sign that recent reported profitability is translating into cash. Free cash flow broadly matching profit supports earnings durability and gives the company greater capacity to fund needs without relying as heavily on external financing.
Bears Say
Revenue Volatility
Large year-to-year revenue swings make the current growth rate harder to treat as a stable trend. Volatile demand or business performance can reduce forecasting confidence, complicate resource planning, and make future margins and earnings less dependable even when the latest TTM results are strong.
Inconsistent Cash Conversion
Although TTM cash generation has improved, the historical pattern of negative or weak operating cash flow shows that accounting profit has not consistently converted into cash. Recurring conversion weakness could constrain self-funded growth and create greater dependence on balance-sheet resources during softer periods.
Earnings Quality Risk
Profitability alongside negative EBIT raises questions about the consistency and operating quality of earnings, while sharp asset and equity movements point to an unstable financial base. These factors make it harder to assess recurring operating power and increase the risk that recent results may not persist.
8158 FAQ
What was China Regenerative Medicine International Limited’s price range in the past 12 months?
What is China Regenerative Medicine International Limited’s market cap?
When is China Regenerative Medicine International Limited’s upcoming earnings report date?
How were China Regenerative Medicine International Limited’s earnings last quarter?
Is China Regenerative Medicine International Limited overvalued?
Does China Regenerative Medicine International Limited pay dividends?
What is China Regenerative Medicine International Limited’s EPS estimate?
How many shares outstanding does China Regenerative Medicine International Limited have?
What happened to China Regenerative Medicine International Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of China Regenerative Medicine International Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
China Regenerative Medicine International Limited
China Regenerative Medicine International Limited operates as an investment holding entity, focusing on the development and distribution of a diverse portfolio of healthcare products and associated services. The company provides extensive health management solutions, covering health condition assessments, detoxification programs, fostering internal bodily balance, nourishing vital organs, and enhancing the immune system. Additionally, its beauty offerings encompass non-surgical medical aesthetics, essential dermatological care, anti-aging skin remedies, hair revitalization, skin firming treatments, localized body contouring, and intimate restoration services. Established in 1995, the organization was previously known as China Bio-Med Regeneration Technology Limited until its rebranding to China Regenerative Medicine International Limited in March 2015. Its headquarters are situated in Tsim Sha Tsui, Hong Kong.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Chuang Wang
- Employees
- 33
- Website
- www.crmi.hk
- Address
- HK
China Regenerative Medicine International Limited (8158) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 6 | 13 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 2 | 0 | 10 |

